Tarsus Pharmaceuticals reinstated with an Overweight at Barclays
Analyst target changes matter most when the new target creates a material gap versus current price or confirms a recent catalyst.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Analyst target changes matter most when the new target creates a material gap versus current price or confirms a recent catalyst.
What happened, with direct paths to the underlying reporting
Barclays upgrades TARS to Overweight; target 110; price 78.23.
Target: $110
Posted price: $78.23
Analyst firm: Barclays
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.